Condensed Consolidated Statements of Cash Flows (unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Cash flows from operating activities:
Net (loss) income	$ (69,804)	$ 18,930
Adjustments to reconcile net (loss) income to net cash used in operating activities:
Depreciation and amortization	15,469	6,172
Stock-based compensation expense	3,761	5,391
Noncash research and development expense (finance lease)	0	1,441
Noncash operating lease expense	5,904	7,423
Gain from sale of priority review voucher	0	(92,930)
Excess inventory reserve	91	2,583
Noncash interest related to debt	156	0
Other non-cash items	(10)	237
Gain on foreign currency exchange rates	(777)	(108)
Changes in operating assets and liabilities:
Prepaid expenses and other assets	(13,528)	(3,689)
Inventory	(7,185)	(5,331)
Accounts payable	1,454	1,260
Accrued expenses and other liabilities	(10,299)	(7,206)
Accrued interest payable under finance lease	2,936	915
Operating lease liabilities	(2,844)	(6,361)
Deferred revenue	0	(85)
Net cash used in operating activities	(74,676)	(71,358)
Cash flows from investing activities:
Purchase of property, plant and equipment	(1,775)	(232)
Purchases of marketable securities	0	(19,610)
Proceeds from maturities of marketable securities	0	4,021
Proceeds from sales of marketable securities	0	5,853
Cash receipts collected	1,120	0
Purchase of intangible assets	0	(868)
Proceeds from sale of priority review voucher	0	92,972
Net cash (used in) provided by investing activities	(655)	82,136
Cash flows from financing activities:
Proceeds from the issuance of debt, net of fees paid to lender	71,316	0
Proceeds allocated to detachable warrants issued in conjunction with debt	2,669	0
Payments of debt issuance costs	(2,250)	0
Proceeds from exercise of stock options and ESPP contributions	0	7
Proceeds from the transfer of invoices	15,120	0
Principal payments on finance leases	(22,210)	(15,280)
Net cash provided by financing activities	64,645	115,176
(Decrease) increase in cash, cash equivalents and restricted cash	(10,686)	125,954
Cash, cash equivalents and restricted cash at beginning of period	274,597	158,445
Cash, cash equivalents and restricted cash at end of period	263,911	284,399
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	212,047	239,045
Restricted cash included in other current assets	3,866	1,417
Restricted cash included in restricted cash and other non-current assets	47,998	43,937
Total cash, cash equivalents and restricted cash	263,911	284,399
Supplemental cash flow disclosures from investing and financing activities:
Purchases of property, plant and equipment included in accounts payable and accrued expenses	0	189
Offering expenses included in accounts payable and accrued expenses	0	523
Priority review voucher expenses accrued or in accounts payable	0	43
Right-of-use assets obtained in exchange for financial lease liabilities	38,669	(214)
Beneficiary interest obtained in transferred invoices	1,680	0
Derecognition of due to factor liabilities	15,120	0
Cash paid during the period for income taxes	1	2
Private Placement
Cash flows from financing activities:
Proceeds from issuance of common stock	0	(196)
Public Offering
Cash flows from financing activities:
Proceeds from issuance of common stock	$ 0	$ 130,645